文献速递消化系统肿瘤

北京大学肿瘤医院胃癌多重免疫组化图谱项目的多维免疫分析揭示PD-1/PD-L1阻断疗效

Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
PubMed 文献 · Eur J Cancer · 2023-06-01

研究基于65种免疫细胞类型的计数和空间特征建立综合风险评分系统,高评分患者较低评分患者的免疫治疗相关无进展生存期和总生存期更优。研究还建立了易用的网络服务器以促进胃癌组织生物标志物探索。

要点

  • 基于65种免疫细胞类型建立综合风险评分,高评分患者免疫治疗相关生存更优。
  • 建立了易用的网络服务器以促进胃癌组织生物标志物探索。

核心结论

  • GMAP项目凸显了组织免疫特征作为免疫治疗决策生物标志物的临床价值。
  • 研究提供了从样本采集到跨站点利用病理组学数据的完整逐步解决方案。

研究设计与样本

  • 研究采用多重光谱成像分析、网络数据存储库和交互共享技术开展GMAP项目。
  • 研究纳入80例胃癌患者,使用15个标志物进行检测。

主要发现

  • 研究基于65种免疫细胞类型的计数和空间特征生成了肿瘤免疫图谱。
  • 高风险评分患者较低风险患者的免疫治疗相关无进展生存期更优(HR:3.19;P < 0.001;中位irPFS:4.87个月 vs 19.87个月)。
  • 高风险评分患者较低风险患者的免疫治疗相关总生存期更优(HR:3.10;P = 0.001;中位irPFS:10.03个月 vs 24.87个月,原文此处写作irPFS,按上下文应为免疫治疗相关总生存期)。

关键数值与推荐

  • 研究基于所选指标建立了综合风险评分系统。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy has resulted in impressive objective response rates and durable tumour remission, but only in a subset of gastric cancer (GC) patients. The PD-L1 combined positive score is the most widely used tissue-based biomarker for anti-PD-1/PD-L1 therapy; however, this unidimensional method has limitations. Next-generation exploration of tissue-based biomarkers for GC requires characterisation of various cellular markers and key immunoregulatory molecule expression in situ. Thus, a complete, stepwise solution covering the entire process from staining samples to cross-site utilisation of pathomics data is urgently needed. METHODS: With the advanced multispectral imaging analysis method, web-based data repository, and interactive sharing technology, we conducted a project entitled Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital (GMAP). We propose a standard pipeline covering sample collection, staining, scanning multispectral images, constructing a spectral library, identifying and phenotyping cells, positioning each element, and quantitatively extracting immune features. We designed an open-access relational database to explore tissue-based biomarkers to determine PD-1/PD-L1 blockade efficacy. RESULTS: The GMAP project detected the functional status and spatial location of more than 50 million cells using 15 markers in 80 GC patients, based on which billions of cell pairs were recognised, highlighting the rich spatial arrangement information and the fine tumour microenvironment structure. We generated a tumour-immune atlas using the count and spatial features of 65 immune cell types. We eventually selected the indicators and built a comprehensive risk-scoring system. Patients with higher risk score showed superior immunotherapy-related progression-free survival (irPFS) (hazard ratio [HR]: 3.19; P < 0.001; median irPFS: 4.87 versus 19.87months, respectively) and immunotherapy-related overall survival (HR: 3.10; P = 0.001; median irPFS: 10.03 versus 24.87months, respectively) compared with lower risk patients, demonstrating their potential for guiding anti-PD-1/PD-L1-based immunotherapy. Importantly, an easy-to-use and versatile web server was built to promote tissue-based biomarker exploration in GC. CONCLUSION: The GMAP project highlighted the clinical value of tissue-based immune features as biomarkers for immunotherapeutic decision-making. We present a well-designed, detailed workflow for the orderly generation and use of a high-quality, spatially resolved pathological database.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jia K, Chen Y, Xie Y, et al. Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy. Eur J Cancer. 2023. PMID: 37343324. doi:10.1016/j.ejca.2023.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。